N and one patient not evaluable tumor response. DISCUSSION The RTI represent a PD173074 new class of small molecule inhibitors of cellular Ren Ren signaling. Recent studies tipifarnib monotherapy with negative results, Macdonald et al Adjei et al, A, Rao et al tipifarnib have been in this study in combination with chemotherapy reported examined. The rationale for evaluating the combination of tipifarnib with gemcitabine and cisplatin was synergistic cytotoxicity Tt pr clinical gemcitabine and tipifarnib Janssen Research Foundation and the observed clinical profile of the right combination of cisplatin and gemcitabine et al Abratt crino Hitt et al, et al Burnett et al Kaufman et al Maase van der et al The main objective of this study to determine the safety and MTD t of oral tipifarnib twice as consecutive days in combination with gemcitabine and cisplatin iv time of day and day of each cycle.
The schedule of gemcitabine followed by cisplatin in this study Hlt weight was CI-1033 used because it is the default calendar on the h at h Most common used in the clinic for advanced NSCLC Soto Parra et al tipifarnib was administered for several days and this alone was planned hlt least s mg bid r in cancer patients Zujewski et al Given the overlapping myelosuppression t drugs, a starting dose of caution mg bid has been placed for this test weight, therefore Ma safety. Previously, a phase I study was t with tipifarnib in combination with gemcitabine plus mgm m Resembled f Interpreted week.
Regarding this study, the recommended dose was mg and offer no pharmacokinetic interactions Patnaik et al, a phase I study tipifarnib day, in combination with cisplatin and gemcitabine day and the day was also Adjei et al evaluated, b out. Mg b.i.d. in this Annex tipifarnib in combination with gemcitabine and cisplatin MGM MGM was determined that the maximum tolerated dose. It was noted, however, reiterated that the administration announces doses of gemcitabine and cisplatin in nine patients with the maximum tolerated dose due to the treatment of nausea, vomiting and fatigue can be reduced k. In our study provide tipifarnib mg The recommended dose for the day. In combination with standard doses of gemcitabine and cisplatin is spoken mg bid dose tipifarnib too high in combination with standard doses of cisplatin and gemcitabine on a daytime schedule, as shown in our study, is t possible to change as other al Patnaik and DLT is determined myelosuppression was the most important.
Dose-limiting toxicity of t Of electrolyte imbalance Nonhaematological e, t Ototoxizit and fatigue. It probably was. The relatively high dose of cisplatin mgm, the h on both pm highest doses administered in this study, audiometry performed at baseline and as clinically indicated, it is likely that the level of T Ototoxizit was little reported. As a patient confinement, Lich developed DLT Class H Rverlust, it is recommended to evaluate formally Ototoxizit t in future studies with this combination. Electrolyte imbalance can forward again Tubulussch because patients pretreated U cisplatin. No drug-drug interaction